International Journal of Infertility & Fetal Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  15 (2024)
Volume  14 (2023)
Volume  13 (2022)
Volume  12 (2021)
Volume  11 (2020)
Volume  10 (2019)
Volume  9 (2018)
Volume  8 (2017)
Volume  7 (2016)
Volume  6 (2015)
Volume  5 (2014)
Volume  4 (2013)
Volume  3 (2012)
Volume  2 (2011)
Volume  1 (2010)
Related articles

VOLUME 4 , ISSUE 3 ( September-December, 2013 ) > List of Articles

REVIEW ARTICLE

Ovarian Hyperstimulation Syndrome

Nalini Mahajan

Citation Information : Mahajan N. Ovarian Hyperstimulation Syndrome. Int J Infertil Fetal Med 2013; 4 (3):71-78.

DOI: 10.5005/jp-journals-10016-1065

License: CC BY-NC 4.0

Published Online: 01-04-2016

Copyright Statement:  Copyright © 2013; The Author(s).


Abstract

How to cite this article

Mahajan N. Ovarian Hyperstimulation Syndrome. Int J Infertility Fetal Med 2013;4(3):71-78.

PDF Share
  1. A fatal case of ovarian hyperstimulation syndrome with cerebral infarction. Pathology 1995 Oct;27(4):344-346.
  2. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Hum Reprod Update 2003 May-Jun;9(3):275-289.
  3. Ovarian hyperstimulation syndrome in a spontaneous pregnancy. Acta Med Port 2011 Dec;24 (Suppl) 3: 635-638.
  4. Odds of ovarian hyperstimulation syndrome (OHSS)—time for reassessment. Hum Fertil (Camb) 2007 Sep;10(3):175-181.
  5. Ovarian hyperstimulation syndrome. Fertil Steril 2008 Nov;90(5 Suppl):S188-S193.
  6. Origin of peritoneal fluid in women: an ovarian exudation product. Br J Obstet Gynaecol 1980 Mar;87(3):177-183.
  7. The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin- 1b, interleukin-6, and vascular endothelial growth factor. Fertil Steril 1999 Mar;71(3):482-489.
  8. A mutation in the follicle-stimulating hormone receptor as a cause of familial spontaneous ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 2004 Apr; 89(4):1255-1258.
  9. Case report: a most peculiar family with spontaneous, recurrent ovarian hyperstimulation syndrome. Gynecol Endocrinol 2012 Aug;28(8):649-651.
  10. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 2000 May;73(5):901-907.
  11. The ovarian hyperstimulation syndrome. Fertil Steril 2000 May;73(5):883-896.
  12. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril 2010 Jul;94(2):389-400.
  13. Relevance of anti-Mullerian hormone measurement in a routine IVF program. Hum Reprod 2008 Mar;23(6):1359-1365.
  14. Serum anti-Mullerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum Reprod 2008 Jan;23(1):160-167.
  15. Ovarian volume and antral follicle count for the prediction of low and hyper responders with in vitro fertilization. Reprod Biol Endocrinol 2007;5:9.
  16. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 2007 Aug;92(8):2931-2937.
  17. Antagonist and agonist coast. Fertil Steril 2012 Mar;97(3):523-526.
  18. Quantification of the effect of pituitary down-regulation on 3D ultrasound predictors of ovarian response. Hum Reprod 2008 Jul;23(7):1538-1544.
  19. Gonadotropinreleasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 2011 May;11(5):CD001750.
  20. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev 2011 Oct 5;(10): CD009154.
  21. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997 Sep;90(3):392-395.
  22. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2009 Apr 15;(2):CD006105.
  23. Criteria of a successful coasting protocol for the prevention of severe ovarian hyperstimulation syndrome. Hum Reprod 2005 Nov;20(11):3167-3172.
  24. Coasting acts through downregulation of VEGF gene expression and protein secretion. Hum Reprod 2004 Jul;19(7):1530-1538.
  25. Coasting (withholding gonadotropins) for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2011 Jun 15;(6):CD002811.
  26. Low dose hCG reduces the incidence of early and severe ovarian hyperstimulation syndrome. Fertil Steril 2006;86(Suppl 2):S182-S183(P-138).
  27. Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization. Fertil Steril 2004;82:841-846.
  28. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 2008 Jan;89(1):84-91.
  29. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study. Fertil Steril 2009 Feb;91(2):365-371.
  30. Elective cryopreservation of embryos at the pronucleate stage in women at risk of ovarian hyperstimulation syndrome may affect the overall pregnancy rate. Fertil Steril 2006 Dec;86(6):1773-1775.
  31. Intravenous albumin for preventing severe ovarian hyperstimulation syndrome: a Cochrane review. Hum Reprod 2002 Dec;17(12):3027-3032.
  32. Administration of intravenous albumin around the time of oocyte retrieval reduces pregnancy rate without preventing ovarian hyperstimulation syndrome: a systematic review and meta-analysis. Gynecol Obstet Invest 2010;70(1):47-54.
  33. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 1998 Jan;341(2-3):309-315.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.